Navigation Links
Sales of Antiretroviral Agents Will Drive Substantial Six Percent Annual Growth in the HIV Drug Market Through 2013
Date:5/19/2009

By 2018, Gilead's Quad Will Become the Highest-Selling Antiretroviral in the World's Major Markets, According to a New Report from Decision Resources

WALTHAM, Mass., May 19 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that sales of antiretroviral agents will drive substantial six percent annual growth in the HIV drug market through 2013 but significant generic erosion of key therapies thereafter will slow annual growth to less than two percent from 2013 to 2018 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

The new Pharmacor report entitled Human Immunodeficiency Virus finds that continued increase in the uptake of Bristol-Myers Squibb/Gilead's Atripla will drive the agent to garner the highest sales of any antiretroviral in 2013. However, from 2013 to 2018, Gilead's Quad will make significant inroads in the HIV market and by 2018 will become the highest-selling antiretroviral drug in the world's major markets, according to the report. Quad will combine favorable safety and efficacy with the dosing convenience of a single daily pill regimen, making it an ideal product for treatment-naive patients.

"The largest commercial opportunities in the HIV market lie in the development of therapies with enhanced convenience, such as co-formulations that minimize the number of pills and frequency of dosing, especially safe and effective therapies that target treatment-naive patients -- the most lucrative segment of the market," said Decision Resources Analyst Jose Avalos, Ph.D. "In addition, agents with reduced long-term toxicities can differentiate themselves in this crowded market."

The report also finds that two novel classes of antiretroviral agents -- the integrase inhibitors and CCR5 antagonists -- have been received with different levels of enthusiasm among interviewed experts and prescribers. Merck's Isentress, the first integrase inhibitor on the market, has been received with great enthusiasm by physicians and patients because of its efficacy, safety, and simple dosing. In contrast, Pfizer's Selzentry, the first-in-class CCR5 antagonist, has experienced significant obstacles that include its limited patient eligibility and the lengthy tropism test required for its prescription. The landscape for CCR5 antagonists is expected to improve, however, once better tropism tests and improved protocols are established.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:

    Decision Resources                          Decision Resources, Inc.
    Christopher Comfort                         Elizabeth Marshall
    781-296-2597                                781-296-2563
    ccomfort@dresources.com                     emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Psychemedics Corporation Announces Sales & Marketing Agreement With Bupa in UK
2. GeckoSystems Reveals Eldercare Capable Personal Robot Sales Forecasts
3. Herbal Supplement Sales Increase in US in 2008
4. U.S. Mobile Robot Co. Reveals Pacific Rim Sales Forecasts
5. Growth in Drug Sales of the Top 10 Pharmaceutical Companies Slowed to its Lowest Level in Years in 2008
6. OrthoSynetics Selects Landslides Sales P3 System as its Corporate Sales System
7. RBC Life Sciences North American Nutritional Supplements and Medical Products Sales Increased, Year Over Year, During the First Quarter of 2009
8. Milestone Scientific Reports Strong Sales Growth in First Quarter 2009 Results
9. Woodward Labs Reports Sales Spike for HandClens(R) Alcohol-Free Hand Sanitizer During Swine Flu Epidemic
10. Driven by Sales of Enbrel, Remicade and Humira, spondyloarthropathies Drug Market Grew to Nearly $2 Billion in 2008
11. Archi-Tech InView Now Supports Managed Care Data, Offering an Interactive Dashboard for On-Demand Sales Planning and Reporting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... Overland Park, KS (PRWEB) , ... June 27, 2016 , ... ... leader in retailers of Eyeglasses . , Millions of individuals in the United ... life, eyeglasses have become a way to both correct vision and make a fashion ...
(Date:6/26/2016)... ... ... legally blind and certified personal trainer is helping to develop a weight loss fitness plan ... fix the two major problems leading the fitness industry today:, , ... They don’t eliminate all the reasons people quit their exercise program ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX users ... - CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 ... Pro X . Simply select a ProHand generator and drag it above media or ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the ... In terms of the latter, setting the bar too high can result in disappointment, ... just slow progress toward their goal. , Research from PsychTests.com reveals ...
(Date:6/24/2016)... ... June 24, 2016 , ... The ... in Dallas that it will receive two significant new grants to support its ... PHA marked its 25th anniversary by recognizing patients, medical professionals and scientists for ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... ITASCA, Ill. , June 23, 2016  In a startling ... states are failing their residents by lacking a comprehensive, proven plan ... , a definitive ranking of how states are tackling the ... rating to only four states – Kentucky , ... and Vermont . Of the 28 failing states, ...
(Date:6/23/2016)... , June 23, 2016 Bracket , a ... its next generation clinical outcomes platform, Bracket eCOA (SM) ... on June 26 – 30, 2016 in Philadelphia ... electronic Clinical Outcome Assessment product of its kind to fully ... Bracket eCOA 6.0 is a flexible platform for ...
(Date:6/23/2016)... -- Guerbet announced today that it has been named a ... One of 12 suppliers to receive the ... of Premier members through exceptional local customer service and ... lower costs. "We ... customer service from Premier," says Massimo Carrara , ...
Breaking Medicine Technology: